Class Is in Session: Assessing the Role of JAK Inhibition to Reach IBD Treatment Goals
Launch Date:
February 12, 2021
Expiration Date:
February 12, 2022
primary audience:
Clinical gastroenterologists and gastroenterology nurse practitioners and physician assistants who are involved in the management of patients with inflammatory bowel disease (ibd)
Relevant Terms:
Gastroenterology, Inflammatory bowel disease
Millie D. Long, MD, MPH
Dr. Millie Long received her medical degree from University of Virginia, Charlottesville, in 2002 and completed her residency in internal medicine and a chief residency at University of Alabama at Birmingham. She then completed fellowships in gastroenterology and hepatology, preventive medicine, and inflammatory bowel disease (IBD), all at University of North Carolina (UNC) and is currently Associate Professor of Medicine in the Department of Medicine and Director of the Gastroenterology and Hepatology Fellowship Program at UNC at Chapel Hill.
Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases Center. Her research interests include prevention of complications of IBD, women’s health, and clinical epidemiology. Dr. Long has contributed numerous peer-reviewed publications, book chapters, and review articles to the medical literature. She is an investigator for the IBD Partners cohort, a prospective cohort focusing on patient-reported outcomes that includes over 15,000 patients living with IBD. She serves as an invited reviewer for journals such as Inflammatory Bowel Diseases, Gastroenterology, and the American Journal of Gastroenterology.
Board certified in internal medicine, preventive medicine, and gastroenterology, Dr. Long is a fellow of the American College of Gastroenterology, where she serves on the Practice Parameters Committee and chairs the Research Committee. She is also a member of the American Gastroenterological Association and the Crohn’s and Colitis Foundation, where she cochairs the Clinical Research Alliance.
Bruce E. Sands, MD, MS
Dr. Bruce Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his undergraduate and medical degrees from Boston University in Massachusetts, and trained in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. After completing his gastroenterology fellowship at the Massachusetts General Hospital (MGH) in Boston, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.
Dr. Sands is widely recognized for his innovative treatment of Crohn’s disease and ulcerative colitis and for his clinical investigations of new therapeutics. Dr. Sands' research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD patients in Rhode Island, a project funded by both the National Institutes of Health and the Centers for Disease Control and Prevention. Dr. Sands has served as an Associate Editor for the journal Gastroenterology, and has published over 200 original manuscripts in leading journals such as Gut, Gastroenterology, and the American Journal of Gastroenterology. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine.
Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn’s and Colitis Foundation of America and served as chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the chair of the International Organization for the Study of IBD (IOIBD). In 2016 Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s and Colitis Foundation of America, that organization’s highest honor.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Millie D. Long, MD, MPH
Consulting Fees: AbbVie Inc., Bristol Myers Squibb Company, Genentech, Inc., Janssen Pharmaceuticals, Inc., Pfizer Inc., Salix Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc., Target PharmaSolutions, Inc., Theravance Biopharma US, Inc., Valeant/Bausch Health
Contracted Research: Pfizer Inc.
Bruce E. Sands, MD, MS
Consulting Fees: Abivax SA, Arena Pharmaceuticals, Inc., Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Celtrion Healthcare Co., Ltd., Cowen Services Company, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline, InDex Pharmaceuticals Holding AB, Ironwood Pharmaceuticals, Inc., Janssen Biotech, Inc., Janssen Pharmaceutica NV, Kallyope Inc., Eli Lilly and Company, Pfizer Inc., Prometheus Biosciences, Inc., Protagonist Therapeutics, Inc., Surrozen Inc., Takeda Pharmaceuticals U.S.A., Inc., Target RWE, USWM Enterprises, LLC, Viela Bio, Inc.
Honoraria: Inotrem S.A., Takeda Pharmaceuticals U.S.A., Inc.
The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Instructions to Receive Credit:
There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity.
A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.
If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com or by visiting: www.pimed.com
Media: Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Clinical Resource Center
Exchangecme.com/IBDManagementResources
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. |
Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS
|
| Additional Recommendations and Requirements | |
| Display Resolution & Color Depth | Resolution – 960 X 768 minimum – 1024 X 768 recommended min. Color Depth |
| Audio | – Microphone – Speakers or headphones – Audio recording support |
| Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |
Related Courses
Assessment Tools and Strategies in Newly Diagnosed Moderate-to-Severe ...
Joint Accreditation Statement In support of improving patient care, this activity has been planned a...
Launches:
Mar 19, 2021
Expires:
Mar 19, 2022
